Amylyx Pharmaceuticals received a Buy rating on its stock, noting that the company benefits from Trump-era tariffs and onshoring trends.
2 reports, 1 independent
Updated Jun 30
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amylyx Pharmaceuticals received a Buy rating on its stock, noting that the company benefits from Trump-era tariffs and onshoring trends.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Amylyx Pharmaceuticals
American biopharmaceutical company
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Leerink partners
U.S. investment bank
Related events
- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- Goldman Sachs and Zeta Interactive noted that tariffs and onshoring benefit AI stocks, citing accelerated Q2 growth and raising price targets.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- Tariffs benefit undervalued AI stocks, and Jim Cramer expressed bullish sentiment regarding Texas Roadhouse.
Coverage
Newest first; wire copies grouped- Insider MonkeyH.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is included in our list of the 11 Best Single